Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04277884
Previous Study | Return to List | Next Study

Firibastat in Treatment-resistant Hypertension (FRESH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04277884
Recruitment Status : Recruiting
First Posted : February 20, 2020
Last Update Posted : September 1, 2020
Sponsor:
Information provided by (Responsible Party):
Quantum Genomics SA

Brief Summary:
This is a double-blind, placebo-controlled, multicenter, efficacy and safety study of firibastat (QGC001) administered po bid over 12 weeks in male and female subjects ≥18 years of age at Screening, with uncontrolled primary HTN. Subjects will be randomized 1:1 to investigational product (IP) and will receive either firibastat (QGC001) or matching placebo on top of their current chronic antihypertensive treatments.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Firibastat Drug: Placebo Phase 3

Detailed Description:
The primary objective of this study is to assess the effects of administration of firibastat (QGC001) 500 mg oral (po) twice daily (bis in die [bid]) on blood pressure (BP) over 12 weeks in subjects with uncontrolled primary HTN.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 502 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects
Actual Study Start Date : June 25, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Firibastat
Capsules
Drug: Firibastat
Oral administration 2×250 mg capsules bid
Other Name: QGC001

Placebo Comparator: Placebo
Matching capsules
Drug: Placebo
Oral administration 2 capsules bid




Primary Outcome Measures :
  1. Systolic Blood Pressure at office (mmHg) [ Time Frame: From Day 1 to Day 84 ]
    Automatic Office Blood Pressure measurement


Secondary Outcome Measures :
  1. Diastolic Blood Pressure at office (mmHg) [ Time Frame: From Day 1 to Day 84 ]
    Automatic Office Blood Pressure measurement

  2. Mean 24-hour ambulatory Systolic Blood Pressure (mmHg) [ Time Frame: From Day 1 to Day 84 ]
    Ambulatory Blood Pressure Monitoring

  3. Mean 24-hour ambulatory Diastolic Blood Pressure (mmHg) [ Time Frame: From Day 1 to Day 84 ]
    Ambulatory Blood Pressure Monitoring



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women ≥18 years of age at Screening
  • Diagnosis of primary HTN for at least 6 months prior to Screening

Exclusion Criteria:

  • Known or suspected secondary HTN (eg, hyperaldosteronism, renovascular HTN, pheochromocytoma, Cushing's disease).
  • Automated office SBP >170 mmHg or DBP >110 mmHg at the Screening or Inclusion Visit (Visit 2, Day 1) and confirmed by a second measurement within 30 minutes to 1 hour.
  • Known hypertensive retinopathy (Keith-Wagener Grade 3 or Grade 4) and/or hypertensive encephalopathy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04277884


Contacts
Layout table for location contacts
Contact: Bruno Besse, MD +33 1 85 34 77 73 bruno.besse@quantum-genomics.com

Locations
Layout table for location information
France
Les Hôpitaux Universitaires de Strasbourg Recruiting
Strasbourg, Grand Est, France, 67091
Contact: Dominique Stephan, MD    +33 3 69 55 09 52    dominique.stephan@chru-strasbourg.fr   
Sponsors and Collaborators
Quantum Genomics SA
Investigators
Layout table for investigator information
Principal Investigator: George Bakris, MD AHA Comprehensive Hypertension Center
Layout table for additonal information
Responsible Party: Quantum Genomics SA
ClinicalTrials.gov Identifier: NCT04277884    
Other Study ID Numbers: QGC001-3QG1
First Posted: February 20, 2020    Key Record Dates
Last Update Posted: September 1, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases